

The Esophageal String Test® Provides Comparable Sensitivity and Specificity to Endoscopy with Biopsy for Monitoring Eosinophilic Esophagitis (EoE)

Test offers EoE patients a simple, clinically proven method to control their disease

PRESS RELEASE – December 15, 2022

AURORA, CO—The Esophageal String Test® (EST®) provides comparable results to endoscopy with tissue biopsy for distinguishing active versus inactive eosinophilic esophagitis (EoE) [1].

During the EST®, a sample is obtained from the esophagus using a capsule-string device called the EnteroTracker®. The sample obtained from the string is then evaluated for concentrations of eosinophil-associated biomarkers eotaxin-3 (Eot-3) and major basic protein-1 (MBP-1) by enzyme-linked immunosorbent assay (ELISA). Statistical modeling, using concentrations of these biomarkers, then predicts the probability that a patient has active esophageal inflammation as seen in EoE. Analysis of the string using this combination of biomarker detection has been found to be highly predictive for determining active versus inactive EoE [1].

In a study published in the American Journal of Gastroenterology with 134 adults and children, scientists compared outcome measures for the string test versus an endoscopy with tissue biopsy using Area Under the Curve (AUC) [1]. The AUC is a value that quantifies a test's capability for detecting a condition or disease. An AUC of over 0.70 indicates that the test or procedure performed can strongly predict or detect the condition of interest. In this study, researchers found that the AUC for detecting active versus inactive disease was 0.83 using the string test, and 0.86 for biopsy [Figure 1]. The researchers concluded that analysis of Eot-3 and MBP-1 using string test is very comparable to tissue biopsy and highly predictive of active esophageal inflammation [1].




Figure 1: Area under the curve (AUC) values for the Esophageal String Test® versus Tissue Biopsy [1].

About EnteroTrack

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company's platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett's Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Contacts

General Info: Brookelynn Stillwell, Brookelynn.Stillwell@enterotrack.com

Investor and Media Contact: Robin Shandas, CEO, robin.shandas@enterotrack.com

¹Ackerman, S. J., et al. (2019). One-hour esophageal string test: A nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis. *American Journal of Gastroenterology*, 114(10), 1614–1625. <https://doi.org/10.14309/ajg.0000000000000371>